- Home
- SANW vs KZIA Comparison
SANW vs KZIA Comparison
Compare SANW & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANW
- KZIA
- Stock Information
- Founded
- SANW 1980
- KZIA 1994
- Country
- SANW United States
- KZIA Australia
- Employees
- SANW N/A
- KZIA N/A
- Industry
- SANW Farming/Seeds/Milling
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SANW Consumer Staples
- KZIA Health Care
- Exchange
- SANW Nasdaq
- KZIA Nasdaq
- Market Cap
- SANW 4.6M
- KZIA 5.1M
- IPO Year
- SANW 2010
- KZIA 1999
- Fundamental
- Price
- SANW $1.77
- KZIA $9.82
- Analyst Decision
- SANW Strong Buy
- KZIA Strong Buy
- Analyst Count
- SANW 1
- KZIA 2
- Target Price
- SANW $25.00
- KZIA $14.00
- AVG Volume (30 Days)
- SANW 100.5K
- KZIA 656.0K
- Earning Date
- SANW 05-15-2025
- KZIA 08-05-2025
- Dividend Yield
- SANW N/A
- KZIA N/A
- EPS Growth
- SANW N/A
- KZIA N/A
- EPS
- SANW N/A
- KZIA N/A
- Revenue
- SANW $54,993,808.00
- KZIA $1,549,158.00
- Revenue This Year
- SANW N/A
- KZIA N/A
- Revenue Next Year
- SANW $17.19
- KZIA N/A
- P/E Ratio
- SANW N/A
- KZIA N/A
- Revenue Growth
- SANW 6.91
- KZIA 248983.08
- 52 Week Low
- SANW $1.50
- KZIA $2.86
- 52 Week High
- SANW $11.60
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- SANW 31.84
- KZIA 58.07
- Support Level
- SANW $1.50
- KZIA $8.66
- Resistance Level
- SANW $2.15
- KZIA $10.37
- Average True Range (ATR)
- SANW 0.23
- KZIA 1.26
- MACD
- SANW 0.10
- KZIA -0.08
- Stochastic Oscillator
- SANW 25.00
- KZIA 64.50
About SANW S&W Seed Company (NV)
S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.